Open Access
Volume 22, 2015
Article Number 10
Number of page(s) 20
Published online 18 February 2015
  1. Abdulhalim B, Wagih MM, Gad AA, Boghdadi G, Nagy RR. 2015. Amniotic membrane graft to conjunctival flap in treatment of non-viral resistant infectious keratitis: a randomised clinical study. British Journal of Ophthalmology, 99(1), 59–63. [CrossRef]
  2. Aichelburg AC, Walochnik J, Assadian O, Prosch H, Steuer A, Perneczky G, Visvesvara GS, Aspöck H, Vetter N. 2008. Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine. Emerging Infectious Diseases, 14, 1743–1746. [CrossRef] [PubMed]
  3. Alsam S, Sissons J, Dudley R, Khan NA. 2005. Mechanisms associated with Acanthamoeba castellanii (T4) phagocytosis. Parasitology Research, 96, 402–409. [CrossRef] [PubMed]
  4. Aqeel Y, Siddiqui R, Khan NA. 2013. Silencing of xylose isomerase and cellulose synthase by siRNA inhibits encystation in Acanthamoeba castellanii. Parasitology Research, 112(3), 1221–1227. [CrossRef] [PubMed]
  5. Arnalich-Montiel F, Martín-Navarro CM, Alió JL, López-Vélez R, Martínez-Carretero E, Valladares B, Piñero JE, Lorenzo-Morales J. 2012. Successful monitoring and treatment of intraocular dissemination of Acanthamoeba with voriconazole. Archives of Ophthalmology, 130, 1474–1475. [CrossRef] [PubMed]
  6. Bacon AS, Frazer DG, Dart JK, Matheson M, Ficker LA, Wright P. 1993. A review of 72 consecutive cases of Acanthamoeba keratitis, 1984–1992. Eye, 7, 719–725. [CrossRef]
  7. Bagorda A, Parent CA. 2008. Eukaryotic chemotaxis at a glance. Journal of Cell Science, 121, 2621–2624. [CrossRef] [PubMed]
  8. Barisani-Asenbauer T, Walochnik J, Mejdoubi L, Binder S. 2012. Successful management of recurrent Acanthamoeba keratitis using topical and systemic miltefosine. Acta Ophthalmologica, 900, doi: 10.1111/j.1755-3768.2012.F095.x.
  9. Beattie TK, Tomlinson A, McFadyen AK, Seal DV, Grimason AM. 2003. Enhanced attachment of Acanthamoeba to extended-wear silicone hydrogel contact lenses: a new risk factor for infection? Ophthalmology, 110, 765–771. [CrossRef] [PubMed]
  10. Blackman HJ, Rao NA, Lemp MA, Visvesvara GS. 1984. Acanthamoeba keratitis successfully treated with penetrating keratoplasty: suggested immunogenic mechanisms of action. Cornea, 3, 125. [CrossRef] [PubMed]
  11. Booton GC, Joslin CE, Shoff M, Tu EY, Kelly DJ, Fuerst PA. 2009. Genotypic identification of Acanthamoeba sp. isolates associated with an outbreak of Acanthamoeba keratitis. Cornea, 28(6), 673–676. [CrossRef] [PubMed]
  12. Bouheraoua N, Gaujoux T, Goldschmidt P, Chaumeil C, Laroche L, Borderie VM. 2013. Prognostic factors associated with the need for surgery in Acanthamoeba keratitis. Cornea, 32, 130–136. [CrossRef] [PubMed]
  13. Brooks SE, Schneider DL. 1985. Oxidative metabolism associated with phagocytosis in Acanthamoeba castellanii. Journal of Protozoology, 32, 330–333. [CrossRef]
  14. Campochiaro PA. 2006. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Therapy, 13, 559–562. [CrossRef] [PubMed]
  15. Cho JH, Na BK, Kim TS, Song CY. 2000. Purification and characterization of an extracellular serine proteinase from Acanthamoeba castellanii. IUBMB Life, 50, 209–214. [CrossRef] [PubMed]
  16. Chusattayanond AD, Boonsilp S, Kasisit J, Boonmee A, Warit S. 2010. Thai Acanthamoeba isolate (T4) induced apoptotic death in neuroblastoma cells via the Bax-mediated pathway. Parasitology International, 59, 512–516. [CrossRef] [PubMed]
  17. Clarke DW, Niederkorn JY. 2006. The immunobiology of Acanthamoeba keratitis. Microbes and Infection, 8(5), 1400–1405. [CrossRef]
  18. Clarke DW, Niederkorn JY. 2006. The pathophysiology of Acanthamoeba keratitis. Trends in Parasitology, 22(4), 175–180. [CrossRef] [PubMed]
  19. Clarke M, Lohan AJ, Liu B, Lagkouvardos I, Roy S, Zafar N, Bertelli C, Schilde C, Kianianmomeni A, Bürglin TR, Frech C, Turcotte B, Kopec KO, Synnott JM, Choo C, Paponov I, Finkler A, Heng Tan CS, Hutchins AP, Weinmeier T, Rattei T, Chu JS, Gimenez G, Irimia M, Rigden DJ, Fitzpatrick DA, Lorenzo-Morales J, Bateman A, Chiu CH, Tang P, Hegemann P, Fromm H, Raoult D, Greub G, Miranda-Saavedra D, Chen N, Nash P, Ginger ML, Horn M, Schaap P, Caler L, Loftus BJ. 2013. Genome of Acanthamoeba castellanii highlights extensive lateral gene transfer and early evolution of tyrosine kinase signaling. Genome Biology, 14(2), R11. [CrossRef] [PubMed]
  20. Cohen EJ, Buchanan HW, Laughrea PA, Adams CP, Galentine PG, Visvesvara GS, Folberg R, Arentsen JJ, Laibson PR. 1985. Diagnosis and management of Acanthamoeba keratitis. American Journal of Ophthalmology, 100(3), 389–395. [CrossRef] [PubMed]
  21. Cohen EJ, Parlato CJ, Arentsen JJ, Genvert GI, Eagle RC Jr, Wieland MR, Laibson PR. 1987. Medical and surgical treatment of Acanthamoeba keratitis. American Journal of Ophthalmology, 103(5), 615–625. [CrossRef] [PubMed]
  22. Cursons RTM, Brown TJ. 1978. Use of cell cultures as an indicator of pathogenicity of free-living amoebae. Journal of Clinical Pathology, 31, 1–11. [CrossRef] [PubMed]
  23. Dart JK, Saw VP, Kilvington S. 2009. Acanthamoeba keratitis: diagnosis and treatment update 2009. American Journal of Ophthalmology, 148(4), 487–499. [CrossRef] [PubMed]
  24. De Jonckheere JF. 1980. Growth characteristics, cytopathic effect in cell culture, and virulence in mice of 36 type strains belonging to 19 different Acanthamoeba spp. Applied and Environmental Microbiology, 39(4), 681–685. [PubMed]
  25. Del Buey MA, Cristóbal JA, Casas P, Goñi P, Clavel A, Mínguez E, Lanchares E, García A, Calvo B. 2012. Evaluation of in vitro efficacy of combined riboflavin and ultraviolet a for Acanthamoeba isolates. American Journal of Ophthalmology, 153(3), 399–404. [CrossRef] [PubMed]
  26. Diaz J, Osuna A, Rosales MJ, Cifuentes J, Mascaro C. 1991. Sucker-like structures in two strains of Acanthamoeba: scanning electron microscopy study. International Journal of Parasitology, 21, 365–367. [CrossRef]
  27. Dudley R, Alsam S, Khan NA. 2007. Cellulose biosynthesis pathway is a potential target in the improved treatment of Acanthamoeba keratitis. Applied Microbiology and Biotechnology, 75(1), 133–140. [CrossRef] [PubMed]
  28. Ferreira GA, Magliano AC, Pral EM, Alfieri SC. 2009. Elastase secretion in Acanthamoeba polyphaga. Acta Tropica, 112, 156–163. [CrossRef] [PubMed]
  29. Ficker L, Seal D, Warhurst D, Wright P. 1990. Acanthamoeba keratitis-resistance to medical therapy. Eye, 4, 835–838. [CrossRef]
  30. Garate M, Cao Z, Bateman E, Panjwani N. 2004. Cloning and characterization of a novel mannose-binding protein of Acanthamoeba. Journal of Biological Chemistry, 279, 29849–29856. [CrossRef]
  31. Garate M, Cubillos I, Marchant J, Panjwani N. 2005. Biochemical characterization and functional studies of Acanthamoeba mannose-binding protein. Infection and Immunity, 73, 5775–5781. [CrossRef] [PubMed]
  32. Garduño-Vieyra L, González-Sánchez CR, Hernández-Da Mota SE. 2011. Ultraviolet-a light and riboflavin therapy for Acanthamoeba keratitis: a case report. Case Reports in Ophthalmology, 2(2), 291–295. [PubMed]
  33. Gast RJ, Ledee DR, Fuerst PA, Byers T. 1996. Subgenus systematics of Acanthamoeba: Four nuclear 18S rDNA sequence types. Journal of Eukaryotic Microbiology, 43, 498–504. [CrossRef]
  34. Griffin JL. 1972. Temperature tolerance of pathogenic and nonpathogenic free-living amoebae. Science, 178, 869–870. [CrossRef] [PubMed]
  35. Grossniklaus HE, Waring GO 4th, Akor C, Castellano-Sanchez AA, Bennett K. 2003. Evaluation of hematoxylin and eosin and special stains for the detection of Acanthamoeba keratitis in penetrating keratoplasties. American Journal of Ophthalmology, 136(3), 520–526. [CrossRef] [PubMed]
  36. Hamburg A, De Jonckheere JF. 1980. Amoebic keratitis. Ophthalmologica, 181, 74. [CrossRef] [PubMed]
  37. He YG, Niederkorn JY, McCulley JP, Stewart GL, Meyer DR, Silvany R, Dougherty J. 1990. In vivo and in vitro collagenolytic activity of Acanthamoeba castellanii. Investigative Ophthalmology and Visual Science, 31, 2235–2240.
  38. Henrissat B, Callebaut I, Mornon JP, Fabrega S, Lehn P, Davies G. 1995. Conserved catalytic machinery and the prediction of a common fold for several families of glycosyl hydrolases. Proceedings of the National Academy of Science USA, 92(15), 7090–7094. [CrossRef]
  39. Henrissat B, Davies G. 1995. Structures and mechanisms of glycosyl hydrolases. Structure, 3(9), 853–859. [CrossRef] [PubMed]
  40. Hong YC, Lee WM, Kong HH, Jeong HJ, Chung DI. 2004. Molecular cloning and characterization of a cDNA encoding a laminin-binding protein (AhLBP) from Acanthamoeba healyi. Experimental Parasitology, 106, 95–102. [CrossRef] [PubMed]
  41. Ikeda Y, Miyazaki D, Yakura K, Kawaguchi A, Ishikura R, Inoue Y, Mito T, Shiraishi A, Ohashi Y, Higaki S, Itahashi M, Fukuda M, Shimomura Y, Yagita K. 2012. Assessment of real-time polymerase chain reaction detection of Acanthamoeba and prognosis determinants of Acanthamoeba keratitis. Ophthalmology, 119, 1111–1119. [CrossRef] [PubMed]
  42. Im K. 1990. Pathogenic free-living amoebae. Korean Journal of Parasitology, 28, 29–39. [CrossRef]
  43. Kao PM, Tung MC, Hsu BM, Tsai HL, She CY, Shen SM, Huang WC. 2013. Real-time PCR method for the detection and quantification of Acanthamoeba species in various types of water samples. Parasitology Research, 112(3), 1131–1136. [CrossRef] [PubMed]
  44. Kandori M, Inoue T, Shimabukuro M, Hayashi H, Hori Y, Maeda N, Tano Y. 2010. Four cases of Acanthamoeba keratitis treated with phototherapeutic keratectomy. Cornea, 29(10), 1199–1202. [CrossRef] [PubMed]
  45. Kashiwabuchi RT, Carvalho FR, Khan YA, de Freitas D, Foronda AS, Hirai FE, Campos MS, McDonnell PJ. 2011. Assessing efficacy of combined riboflavin and UV-A light (365 nm) treatment of Acanthamoeba trophozoites. Investigative Ophthalmology and Visual Science, 52(13), 9333–9338. [CrossRef]
  46. Khan NA. 2009. Acanthamoeba – Biology and Pathogenesis. Caister Academic Press: Norfolk, Great Britain, 290 p.
  47. Khan NA. 2006. Acanthamoeba: biology and increasing importance in human health. FEMS Microbiology Reviews, 30, 564–595. [CrossRef] [PubMed]
  48. Khan NA. 2001. Pathogenicity, morphology and differentiation of Acanthamoeba. Current Microbiology, 43, 391–395. [CrossRef] [PubMed]
  49. Khan YA, Kashiwabuchi RT, Martins SA, Castro-Combs JM, Kalyani S, Stanley P, Flikier D, Behrens A. 2011. Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis: report of 3 cases. Ophthalmology, 118(2), 324–331. [CrossRef] [PubMed]
  50. Kim JY, Na BK, Song KJ, Park MH, Park YK, Kim TS. 2012. Functional expression and characterization of an iron-containing superoxide dismutase of Acanthamoeba castellanii. Parasitology Research, 111, 1673–1682. [CrossRef] [PubMed]
  51. Kitzmann AS, Goins KM, Sutphin JE, Wagoner MD. 2009. Keratoplasty for treatment of Acanthamoeba keratitis. Ophthalmology, 116, 864–869. [CrossRef] [PubMed]
  52. Lim N, Goh D, Bunce C, Xing W, Fraenkel G, Poole TR, Ficker L. 2008. Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. American Journal of Ophthalmology, 145, 130–135. [CrossRef] [PubMed]
  53. Lorenzo-Morales J, Kliescikova J, Martínez-Carretero E, De Pablos LM, Profotova B, Nohynkova E, Osuna A, Valladares B. 2008. Glycogen phosphorylase in Acanthamoeba spp.: determining the role of the enzyme during the encystment process using RNA interference. Eukaryotic Cell, 7(3), 509–517. [CrossRef] [PubMed]
  54. Lorenzo-Morales J, Martín-Navarro CM, López-Arencibia A, Arnalich-Montiel F, Piñero JE, Valladares B. 2013. Acanthamoeba keratitis: an emerging disease gathering importance worldwide? Trends in Parasitology, 29(4), 181–187. [CrossRef] [PubMed]
  55. Lorenzo-Morales J, Ortega-Rivas A, Foronda P, Abreu-Acosta N, Ballart D, Martínez E, Valladares B. 2005. RNA interference (RNAi) for the silencing of extracellular serine proteases genes in Acanthamoeba: Molecular analysis and effect on pathogenecity. Molecular and Biochemical Parasitology, 144, 10–15. [CrossRef] [PubMed]
  56. Marciano-Cabral F, Cabral G. 2003. Acanthamoeba spp. as agents of disease in humans. Clinical Microbiology Reviews, 16(2), 273–307. [CrossRef] [PubMed]
  57. Martín-Navarro CM, Lorenzo-Morales J, López-Arencibia A, Reyes-Batlle M, Piñero JE, Valladares B, Maciver SK. 2014. Evaluation of Acanthamoeba myosin-IC as a potential therapeutic target. Antimicrobial Agents and Chemotherapy, 58(4), 2150–2155. [CrossRef] [PubMed]
  58. Martín-Navarro CM, Lorenzo-Morales J, Machin RP, López-Arencibia A, García-Castellano JM, de Fuentes I, Loftus B, Maciver SK, Valladares B, Piñero JE. 2013. Inhibition of HMG-CoA reductase and the application of statins as a novel effective therapeutic approach against Acanthamoeba infections. Antimicrobial Agents and Chemotherapy, 57(1), 375–381. [CrossRef] [PubMed]
  59. Mathers WD, Nelson SE, Lane JL, Wilson ME, Allen RC, Folberg R. 2000. Confirmation of confocal microscopy diagnosis of Acanthamoeba keratitis using polymerase chain reaction analysis. Archives of Ophthalmology, 118, 178–183. [CrossRef] [PubMed]
  60. Mattana A, Cappai V, Alberti L, Serra C, Fiori PL, Cappuccinelli P. 2002. ADP and other metabolites released from Acanthamoeba castellanii lead to human monocytic cell death through apoptosis and stimulate the secretion of proinflammatory cytokines. Infection and Immunity, 70, 4424–4432. [CrossRef] [PubMed]
  61. Maubon D, Dubosson M, Chiquet C, Yera H, Brenier-Pinchart MP, Cornet M, Savy O, Renard E, Pelloux H. 2012. A one-step multiplex PCR for Acanthamoeba keratitis diagnosis and quality samples control. Investigative Ophthalmology and Visual Science, 53(6), 2866–2872. [CrossRef]
  62. Mazur T, Hadas E, Iwanicka I. 1995. The duration of the cyst stage and the viability and virulence of Acanthamoeba isolates. Tropical Medicine and Parasitology, 46, 106–108.
  63. McClellan K, Howard K, Niederkorn JY, Alizadeh H. 2001. Effect of steroids on Acanthamoeba cysts and trophozoites. Investigative Ophthalmology and Visual Science, 42, 2885–2893.
  64. Michalek M, Sönnichsen FD, Wechselberger R, Dingley AJ, Hung CW, Kopp A, Wienk H, Simanski M, Herbst R, Lorenzen I, Marciano-Cabral F, Gelhaus C, Gutsmann T, Tholey A, Grötzinger J, Leippe M. 2013. Structure and function of a unique pore-forming protein from a pathogenic Acanthamoeba. Nature Chemical Biology, 9, 37–42. [CrossRef] [PubMed]
  65. Moon EK, Hong Y, Chung DI, Goo YK, Kong HH. 2014. Down-regulation of cellulose synthase inhibits the formation of endocysts in Acanthamoeba. Korean Journal of Parasitology, 52(2), 131–135. [CrossRef]
  66. Mortazavi PN, Keisary E, Loh LN, Jung SY, Khan NA. 2011. Possible roles of phospholipase A2 in the biological activities of Acanthamoeba castellanii (T4 genotype). Protist, 162, 168–176. [CrossRef] [PubMed]
  67. Na BK, Cho JH, Song CY, Kim TS. 2002. Degradation of immunoglobulins, protease inhibitors and interleukin-1 by a secretory proteinase of Acanthamoeba castellanii. Korean Journal of Parasitology, 40, 93–99. [CrossRef]
  68. Na BK, Kim JC, Song CY. 2001. Characterization and pathogenetic role of proteinase from Acanthamoeba castellanii. Microbial Pathogenesis, 30, 39–48. [CrossRef] [PubMed]
  69. Nguyen TH, Weisenthal RW, Florakis GJ, Reidy JJ, Gaster RN, Tom D. 2010. Penetrating keratoplasty in active Acanthamoeba keratitis. Cornea, 29, 1000–1004. [CrossRef] [PubMed]
  70. Niederkorn JY, Alizadeh H, Leher H, McCulley JP. 1999. The pathogenesis of Acanthamoeba keratitis. Microbes and Infection, 1, 437–443. [CrossRef]
  71. Page FC, Siemensma FJ. 1991. Nackte Rhizopoda und Heliozoea, in Protozoenfauna, Band 2, Matthes D (Hrsg.). G. Fischer: Stuttgart.
  72. Parthasarathy A, Tan DT. 2007. Deep lamellar keratoplasty for Acanthamoeba keratitis. Cornea, 26(8), 1021–1023. [CrossRef] [PubMed]
  73. Pellegrin JL, Ortega-Barria E, Barza M, Baum J, Pereira ME. 1991. Neuraminidase activity in Acanthamoeba species trophozoites and cysts. Investigative Ophthalmology and Visual Science, 32, 3061–3066.
  74. Pellegrin JL, Ortega-Barria E, Prioli RP, Meijia JS, Pereira ME. 1992. The neuraminidases of Trypanosoma cruzi and Acanthamoeba castellanii are immunologically related. Tropical Medicine and Parasitology, 43, 33–37.
  75. Pérez-Serrano J, Martínez J, Pérez B, Bernadina WE, Rodríguez-Caabeiro F. 2000. In vitro shock response to different stressors in free living and pathogenic Acanthamoeba. International Journal of Parasitology, 30(7), 829–835. [CrossRef]
  76. Pettit DA, Williamson J, Cabral GA, Marciano-Cabral F. 1996. In vitro destruction of nerve cell cultures by Acanthamoeba spp.: a transmission and scanning electron microscopy study. Journal of Parasitology, 82, 769–777. [CrossRef]
  77. Podlipaeva IuI, Shmakov LA, Gilichinskiĭ DA, Gudkov AV. 2006. Heat shock protein of HSP70 family revealed in some contemporary freshwater Amoebae and in Acanthamoeba sp. from cysts isolated from permafrost samples. Tsitologiia, 48(8), 691–694.
  78. Polat ZA, Obwaller A, Vural A, Walochnik J. 2012. Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. Parasitology Research, 110(2), 515–522. [CrossRef] [PubMed]
  79. Polat ZA, Walochnik J, Obwaller A, Vural A, Dursun A, Arici MK. 2014. Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis. Clinical and Experimental Ophthalmology, 42(2), 151–158. [CrossRef]
  80. Pussard M, Pons R. 1977. Morphologie de la paroi kystique et taxonomie du genre Acanthamoeba (Protozoa, Amoebida). Protistologica, 8, 557–598.
  81. Qvarnstrom Y, Visvesvara GS, Sriram R, da Silva AJ. 2006. Multiplex real-time PCR assay for simultaneous detection of Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria fowleri. Journal of Clinical Microbiology, 44(10), 3589–3595. [CrossRef] [PubMed]
  82. Ren M, Gao L, Wu X. 2010. TLR4: the receptor bridging Acanthamoeba challenge and intracellular inflammatory responses in human corneal cell lines. Immunology and Cell Biology, 88, 529–536. [CrossRef] [PubMed]
  83. Ren MY, Wu XY. 2011. Toll-like receptor 4 signalling pathway activation in a rat model of Acanthamoeba keratitis. Parasite Immunology, 33, 25–33. [CrossRef] [PubMed]
  84. Rivière D, Szczebara FM, Berjeaud JM, Frère J, Héchard Y. 2006. Development of a real-time PCR assay for quantification of Acanthamoeba trophozoites and cysts. Journal of Microbiological Methods, 64(1), 78–83. [CrossRef] [PubMed]
  85. Robaei D, Carnt N, Minassian DC, Dart JK. 2014. The impact of topical corticosteroid use before diagnosis on the outcome of Acanthamoeba keratitis. Ophthalmology, 121(7), 1383–1388. [CrossRef] [PubMed]
  86. Roberts CW, Henriquez FL. 2010. Drug target identification, validation, characterisation and exploitation for treatment of Acanthamoeba (species) infections. Experimental Parasitology, 126, 91–96. [CrossRef] [PubMed]
  87. Rocha-Azevedo BD, Jamerson M, Cabral GA, Silva-Filho FC, Marciano-Cabral F. 2009. Acanthamoeba interaction with extracellular matrix glycoproteins: biological and biochemical characterization and role in cytotoxicity and invasiveness. Journal of Eukaryotic Microbiology, 56, 270–278. [CrossRef]
  88. Rondinone CM. 2006. Therapeutic potential of RNAi in metabolic diseases. Biotechniques, 40, 31–36. [CrossRef]
  89. Saheb E, Trzyna W, Bush J. 2013. An Acanthamoeba castellanii metacaspase associates with the contractile vacuole and functions in osmoregulation. Experimental Parasitology, 133, 314–326. [CrossRef] [PubMed]
  90. Schroeder JM, Booton GC, Hay J, Niszl IA, Seal DV, Markus MB, Fuerst PA, Byers TJ. 2001. Use of subgenic 18S ribosomal DNA PCR and sequencing for genus and genotype identification of Acanthamoeba from humans with keratitis and from sewage sludge. Journal of Clinical Microbiology, 39, 1903–1911. [CrossRef] [PubMed]
  91. Schuster FL. 2002. Cultivation of pathogenic and opportunistic free-living amebas. Clinical Microbiology Reviews, 15(3), 342–354. [CrossRef] [PubMed]
  92. Schuster FL, Levandowsky M. 1996. Chemosensory responses of Acanthamoeba castellanii: visual analysis of random movement and responses to chemical signals. Journal of Eukaryotic Microbiology, 43, 150–158. [CrossRef]
  93. Siddiqui R, Iqbal J, Maugueret MJ, Khan NA. 2012. The role of Src kinase in the biology and pathogenesis of Acanthamoeba castellanii. Parasites and Vectors, 5, 112. [CrossRef]
  94. Sissons J, Alsam S, Jayasekera S, Khan NA. 2004. Ecto-ATPases of clinical and non-clinical isolates of Acanthamoeba. Microbial Pathogenesis, 37, 231–239. [CrossRef] [PubMed]
  95. Sissons J, Alsam S, Jayasekera S, Kim KS, Stins M, Khan NA. 2004. Acanthamoeba induces cell-cycle arrest in the host cells. Journal of Medical Microbiology, 53, 711–717. [CrossRef] [PubMed]
  96. Sissons J, Kim KS, Stins M, Jayasekera S, Alsam S, Khan NA. 2005. Acanthamoeba castellanii induces host cell death via a phosphatidylinositol 3-kinase-dependent mechanism. Infection and. Immunity, 73, 2704–2708. [CrossRef] [PubMed]
  97. Stothard DR, Schroeder-Diedrich JM, Awwad MH, Gast RJ, Ledee DR, Rodriguez-Zaragoza S, Dean CL, Fuerst PA, Byers TJ. 1998. The evolutionary history of the genus Acanthamoeba and the identification of eight new 18S rDNA gene sequence types. Journal of Eukaryotic Microbiology, 45, 45–54. [CrossRef]
  98. Sun X, Zhang Y, Li R, Wang Z, Luo S, Gao M, Deng S, Chen W, Jin X. 2006. Acanthamoeba keratitis: clinical characteristics and management. Ophthalmology, 113, 412–416. [CrossRef] [PubMed]
  99. Szentmáry N, Goebels S, Matoula P, Schirra F, Seitz B. 2012. Die Akanthamöbenkeratitis – ein seltenes und oft spät diagnostiziziertes Chamäleon. Klinische Monatsblätter für Augenheilkunde, 229(5), 521–528. [CrossRef]
  100. Taylor WM, Pidherney MS, Alizadeh H, Niederkorn JY. 1995. In vitro characterization of Acanthamoeba castellanii cytopathic effect. Journal of Parasitology, 81, 603–609. [CrossRef]
  101. Thomas PA, Kuriakose T. 1990. Rapid detection of Acanthamoeba cysts in corneal scrapings by lactophenol cotton blue staining. Archives of Ophthalmology, 108(2), 168. [CrossRef] [PubMed]
  102. Tripathi T, Abdi M, Alizadeh H. 2013. Role of phospholipase A2 (PLA2) inhibitors in attenuating apoptosis of the corneal epithelial cells and mitigation of Acanthamoeba keratitis. Experimental Eye Research, 113, 182–191. [CrossRef] [PubMed]
  103. Trzyna WC, Legras XD, Cordingley JS. 2008. A type-1 metacaspase from Acanthamoeba castellanii. Microbiology Research, 163, 414–423. [CrossRef]
  104. Tu EY, Joslin CE, Sugar J, Shoff ME, Booton GC. 2008. Prognostic factors affecting visual outcome in Acanthamoeba keratitis. Ophthalmology, 115, 1998–2003. [CrossRef] [PubMed]
  105. Tu EY, Joslin CE, Nijm LM, Feder RS, Jain S, Shoff ME. 2009. Polymicrobial keratitis: Acanthamoeba and infectious crystalline keratopathy. American Journal of Ophthalmology, 148, 13–19. [CrossRef] [PubMed]
  106. Turner NA, Russell AD, Furr JR, Lloyd D. 2004. Resistance, biguanide sorption and biguanide-induced pentose leakage during encystment of Acanthamoeba castellanii. Journal of Applied Microbiology, 96(6), 1287–1295. [CrossRef] [PubMed]
  107. Turner NA, Russell AD, Furr JR, Lloyd D. 2000. Emergence of resistance to biocides during differentiation of Acanthamoeba castellanii. Journal of Antimicrobials and Chemotherapy, 46(1), 27–34. [CrossRef]
  108. Ueki N, Eguchi H, Oogi Y, Shiota H, Yamane S, Umazume H, Mizui K. 2009. Three cases of Acanthamoeba keratitis diagnosed and treated in the early stage. Journal of Medical Investigation, 56(3–4), 166–169. [CrossRef]
  109. Van Klink F, Alizadeh H, Stewart GL, Pidherney MS, Silvany RE, He Y, McCulley JP, Niederkorn JY. 1992. Characterization and pathogenic potential of a soil isolate and an ocular isolate of Acanthamoeba castellanii in relation to Acanthamoeba keratitis. Current Eye Research, 11, 1207–2012. [CrossRef] [PubMed]
  110. Villani E, Baudouin C, Efron N, Hamrah P, Kojima T, Patel SV, Pflugfelder SC, Zhivov A, Dogru M. 2014. In vivo confocal microscopy of the ocular surface: from bench to bedside. Current Eye Research, 39(3), 213–231. [CrossRef] [PubMed]
  111. Visvesvara GS, Moura H, Schuster FL. 2007. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunology and Medical Microbiology, 50(1), 1–26. [CrossRef] [PubMed]
  112. Visvesvara GS. 2010. Amebic meningoencephalitides and keratitis: challenges in diagnosis and treatment. Current Opinion in Infectious Diseases, 23(6), 590–594. [CrossRef] [PubMed]
  113. Walochnik J, Michel R, Aspöck H. 2004. A molecular biological approach to the phylogenetic position of the genus Hyperamoeba. Journal of Eukaryotic Microbiology, 51(4), 433–440. [CrossRef]
  114. Walochnik J, Obwaller A, Aspöck H. 2000. Correlations between morphological, molecular biological, and physiological characteristics in clinical and nonclinical isolates of Acanthamoeba spp. Applied and Environmental Microbiology, 66(10), 4408–4413. [CrossRef] [PubMed]
  115. Walochnik J, Obwaller A, Haller-Schober EM, Aspöck H. 2001. Anti-Acanthamoeba IgG, IgM, and IgA immunoreactivities in correlation to strain pathogenicity. Parasitology Research, 87(8), 651–656. [CrossRef] [PubMed]
  116. Walochnik J, Scheikl U, Haller-Schober EM. 2014. Twenty years of Acanthamoeba diagnostics in Austria. Journal of Eukaryotic Microbiology, 2014 July 22. doi: 10.1111/jeu.12149. [Epub ahead of print].
  117. Wynter-Allison Z, Lorenzo Morales J, Calder D, Radlein K, Ortega-Rivas A, Lindo JF. 2005. Acanthamoeba infection as a cause of severe keratitis in a soft contact lens wearer in Jamaica. American Journal of Tropical Medicine and Hygiene, 73(1), 92–94.
  118. Zegans ME, Becker HI, Budzik J, O’Toole G. 2002. The role of bacterial biofilms in ocular infections. DNA and Cell Biology, 21, 415–420. [CrossRef] [PubMed]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.